Storyline
GSK’s hepatitis B drug achieves functional cure in nearly one-fifth of patients in phase 3 trials
GSK and Ionis Pharmaceuticals reported phase 3 trial results for bepirovirsen, showing nearly 20% of patients with chronic hepatitis B achieved a functional cure.
Published 2026-05-28 08:39 UTCUpdated 2026-05-28 16:01 UTC
Current brief openSource links open
This current storyline is open here with summary, metadata, source links, continuity context, and full evidence. Paid is for compare-over-time, alerts, exports, and workflow.
No card needed for the free brief.
Evidence trail (top sources)
top sources (3 domains)domains are deduped. counts indicate coverage, not truth.3 top sources shown
Overview
GSK and Ionis Pharmaceuticals reported phase 3 trial results for bepirovirsen, showing nearly 20% of patients with chronic hepatitis B achieved a functional cure.
Score total
1.31
Momentum 24h
3
Posts
3
Origins
3
Source types
1
Duplicate ratio
0%
Why now
- Phase 3 trial results have just been released, confirming efficacy in a large patient population.
- The data represent a major advancement in a field with few effective cures.
- GSK and Ionis are positioned to potentially bring a first-in-class hepatitis B cure to market.
Why it matters
- Hepatitis B affects millions globally with limited curative treatments.
- A functional cure could greatly reduce disease burden and improve outcomes.
- Positive phase 3 data may speed regulatory approval and treatment availability.
Continuity snapshot
- Trend status: insufficient_history.
- Continuity stage: emerging_confirmed.
- Current status: open.
- 3 current source-linked posts are attached to this storyline.
All evidence
All evidence
GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’
BioPharma Dive · biopharmadive.com · 2026-05-28 16:01 UTC
GSK hails 'unprecedented' cure rates with hep B drug
pharmaphorum · pharmaphorum.com · 2026-05-28 11:55 UTC
GSK is pulling back the curtain on the phase 3 success of its chronic hepatitis B drug bepirovirsen, revealing that nearly one-fifth of all treated patients across two trials we...
Fierce Biotech · fiercebiotech.com · 2026-05-28 08:39 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 3Origin domains: 3Duplicates: -
Showing 3 / 0
Top publishers (this list)
- BioPharma Dive (1)
- pharmaphorum (1)
- Fierce Biotech (1)
Top origin domains (this list)
- biopharmadive.com (1)
- pharmaphorum.com (1)
- fiercebiotech.com (1)